|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Atherosclerosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Inflammation | |||||
| 3 | More general conditions related to this trial | ||||
| Arterial Occlusive Diseases | |||||
| Arteriosclerosis | |||||
| Cardiovascular Diseases | |||||
| Pathologic Processes | |||||
| Vascular Diseases | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Atorvastatin | |||||
| Fluvastatin | |||||
| NK 104 | |||||
| Pravastatin | |||||
| Rosuvastatin | |||||
| Simvastatin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anticholesteremic Agents | |||||
| Antilipemic Agents | |||||
| Antimetabolites | |||||
| Enzyme Inhibitors | |||||
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Kurume University | |||||